CLAIMS

1. Use of a combination of aTh1 composition and an HIV-antigen in the preparation of a medicament for reducing the viral load in a patient with HIV, in which at least one dose of a aTh1 composition and at least one dose of an HIV-antigen are to be administered to the patient, in which the titer of circulating CD4+ Th1 memory cells that are resistant to HIV infection are increased in the patient and the viral load is decreased in the patient.

2. Use according to Claim 1, in which the aTh1 composition and the HIV-antigen are to be administered separately.

3. Use according to Claim 1, in which the aTh1 composition and the HIV-antigen are to be administered intradermally.

4. Use according to Claim 1, in which two or more doses of the aTh1 composition and HIV-antigens are to be administered intradermally.

5. Use according to Claim 1, in which an intravenous dose of the Th1 composition is to be further administered.

6. Use according to Claim 1, in which the period between administering the doses in the cycles is between about 3 days and about 5 days.

7. Use according to Claim 1, in which the patient is to be concurrently treated with HAART.

8. Use according to Claim 1, in which the latent viral load is reduced or eliminated in the patient.

9. Use of a aTh1 composition in the preparation of a medicament for reducing or eliminating HIV-virus from a patient, in which the aTh1 is to be administered to a patient in escalating intravenous doses, and in which the patient is to be concurrently treated with HAART.

10. Use according to Claim 9, in which at least one intradermal dose of a composition comprising living CD4 immune cells comprising activated allogenic CD4+ Th1 memory cells and an HIV antigen is to be administered to the patient and in which at least one intravenous dose of the composition is to be administered to the patient.

11. Use according to Claim 9, in which at least one dose of a aTh1 composition and at least one dose of an HIV-antigen are to be administered to the patient.

12. Use according to Claim 9, in which

(a) at least one intradermal dose of a composition comprising living CD4 immune cells comprising activated allogenic CD4+ Th1 memory cells and an HIV antigen is to be administered to the patient and in which at least one intravenous dose of the composition is to be administered to the patient; and

(b) in which at least one dose of a aTh1 composition and at least one dose of an HIV-antigen are to be administered to the patient.

13. Use according to Claim 9, in which the HAART is halted and the patient is monitored for CD4+ cells and the viral load.

14. Use according to Claim 13, in which HAART is to be reinstated if a viral spike is detected in the patient.

15. A kit comprising components of a therapeutic HIV vaccine wherein the kit comprises intradermal doses of a aTh1 composition, intravenous doses of a aTh1 composition and one or more HIV-antigens.

16. A kit according to Claim 15, in which the kit further comprises components of HAART.

17. A kit according to Claim 15, in which the intradermal composition is divided into single dose packages with the same amount of composition in each package.

18. A kit according to Claim 15, in which the intravenous composition is divided into single dose packages with differing amounts of the composition in each package.

19. A kit according to Claim 15, in which the single dose packages of each cycle are labeled and are configured to have increasing amounts of the composition.

20. A composition comprising:

a aTh1 composition comprising an alloantigen, a molecule that interacts with CD40 surface receptor and Type I cytokines; and

at least one or more HIV-antigens.

21. An AVI composition comprising:

a aTh1 composition comprising an alloantigen, a molecule that interacts with CD40 surface receptor and Type I cytokines; and

at least one or more anti-retroviral drugs.

22. A composition according to Claim 21 further comprising one or more HIV-antigens.

CLAIMS

1. Use of a combination of a composition and an HIV-antigen in the preparation of a medicament for reducing the viral load in a patient with HIV, the composition comprising living CD4 immune cells comprising activated allogeneic $CD4^+$ Th1 memory cells, in which at least one dose of the composition and at least one dose of the HIV-antigen are to be administered intradermally to the patient, in which the titer of circulating CD4+ Th1 memory cells that are resistant to HIV infection are increased in the patient and the viral load is decreased in the patient, and in which at least two doses of the composition are to be administered intravenously to the patient in escalating doses.

2. Use according to Claim 1, in which the intradermal doses of the composition and the HIV-antigen are to be administered separately to the patient.

3. Use according to Claim 1, in which two or more doses of the composition and the HIV-antigen are to be administered intradermally to the patient.

4. Use according to Claim 1, in which a period between administering intradermal doses of both the at least one dose of the composition and the at least one dose of the HIV-antigen is between about 3 days and about 5 days.

5. Use according to Claim 1, in which the patient is to be concurrently treated with HAART.

6. Use according to Claim 1, in which a latent viral load is reduced or eliminated in the patient.

7. Use of a composition in the preparation of a medicament for reducing or eliminating HIV-virus from a patient, in which at least one intradermal dose of the composition and an HIV-antigen is to be administered to the patient, the composition comprising living CD4 immune cells comprising activated allogeneic $CD4^+$ Th1 memory cells; in which at least two intravenous doses of the composition are to be administered to the patient in escalating doses, and in which the patient is to be concurrently treated with HAART.

8. Use according to Claim 7, in which the HAART is halted and the patient is monitored for CD4+ cells and a viral load.

9. Use according to Claim 8, in which the HAART is to be reinstated if a viral spike is detected in the patient.

10. A kit comprising components of a therapeutic HIV vaccine, the kit comprising intradermal doses of a composition comprising living CD4 immune cells comprising activated allogeneic $CD4^+$ Th1 memory cells; in which the intradermal doses are divided into single dose packages with the same amount of the composition in each package, intravenous doses of the composition, in which the intravenous doses are divided into single dose packages with differing amounts of the composition in each package and one or more HIV-antigens.

11. A kit according to Claim 10, further comprising components of HAART.

18. A kit according to Claim 10, in which the single dose packages of the intravenous doses are configured to have increasing amounts of the composition.